vs

Side-by-side financial comparison of BUCKLE INC (BKE) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $320.8M, roughly 1.9× BUCKLE INC). Royalty Pharma plc runs the higher net margin — 34.4% vs 15.2%, a 19.3% gap on every dollar of revenue. On growth, BUCKLE INC posted the faster year-over-year revenue change (9.3% vs 4.8%).

The Buckle, Inc., is an American fashion retailer selling clothing, footwear, and accessories for men, women, and children. The company operates 451 stores in 42 states throughout the United States of America, under the names Buckle and The Buckle. Buckle markets brand name and private label apparel, including denim, other casual bottoms, tops and shirts, dresses and rompers, sportswear and athleisure, outerwear, footwear, swimwear, fragrances, sunglasses, bags and purses, wallets, and other ...

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

BKE vs RPRX — Head-to-Head

Bigger by revenue
RPRX
RPRX
1.9× larger
RPRX
$622.0M
$320.8M
BKE
Growing faster (revenue YoY)
BKE
BKE
+4.5% gap
BKE
9.3%
4.8%
RPRX
Higher net margin
RPRX
RPRX
19.3% more per $
RPRX
34.4%
15.2%
BKE

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
BKE
BKE
RPRX
RPRX
Revenue
$320.8M
$622.0M
Net Profit
$48.7M
$214.2M
Gross Margin
48.0%
Operating Margin
19.0%
62.4%
Net Margin
15.2%
34.4%
Revenue YoY
9.3%
4.8%
Net Profit YoY
10.3%
2.9%
EPS (diluted)
$0.96
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BKE
BKE
RPRX
RPRX
Q4 25
$320.8M
$622.0M
Q3 25
$305.7M
$609.3M
Q2 25
$272.1M
$578.7M
Q1 25
$379.2M
$568.2M
Q4 24
$593.6M
Q3 24
$564.7M
Q2 24
$537.3M
Q1 24
$568.0M
Net Profit
BKE
BKE
RPRX
RPRX
Q4 25
$48.7M
$214.2M
Q3 25
$45.0M
$288.2M
Q2 25
$35.2M
$30.2M
Q1 25
$77.2M
$238.3M
Q4 24
$208.2M
Q3 24
$544.0M
Q2 24
$102.0M
Q1 24
$4.8M
Gross Margin
BKE
BKE
RPRX
RPRX
Q4 25
48.0%
Q3 25
47.4%
Q2 25
46.7%
Q1 25
52.6%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
BKE
BKE
RPRX
RPRX
Q4 25
19.0%
62.4%
Q3 25
18.4%
70.1%
Q2 25
16.0%
36.3%
Q1 25
25.4%
94.0%
Q4 24
60.9%
Q3 24
Q2 24
50.2%
Q1 24
-13.0%
Net Margin
BKE
BKE
RPRX
RPRX
Q4 25
15.2%
34.4%
Q3 25
14.7%
47.3%
Q2 25
12.9%
5.2%
Q1 25
20.4%
41.9%
Q4 24
35.1%
Q3 24
96.3%
Q2 24
19.0%
Q1 24
0.8%
EPS (diluted)
BKE
BKE
RPRX
RPRX
Q4 25
$0.96
$0.49
Q3 25
$0.89
$0.67
Q2 25
$0.70
$0.07
Q1 25
$1.54
$0.55
Q4 24
$0.46
Q3 24
$1.21
Q2 24
$0.23
Q1 24
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BKE
BKE
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$24.0M
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$510.7M
$9.7B
Total Assets
$1.1B
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BKE
BKE
RPRX
RPRX
Q4 25
$24.0M
$618.7M
Q3 25
$22.1M
$938.9M
Q2 25
$22.9M
$631.9M
Q1 25
$23.8M
$1.1B
Q4 24
$929.0M
Q3 24
$950.1M
Q2 24
$1.8B
Q1 24
$843.0M
Total Debt
BKE
BKE
RPRX
RPRX
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Q1 24
$6.1B
Stockholders' Equity
BKE
BKE
RPRX
RPRX
Q4 25
$510.7M
$9.7B
Q3 25
$476.2M
$9.6B
Q2 25
$445.3M
$9.5B
Q1 25
$423.8M
$9.8B
Q4 24
$10.3B
Q3 24
$10.3B
Q2 24
$9.8B
Q1 24
$9.9B
Total Assets
BKE
BKE
RPRX
RPRX
Q4 25
$1.1B
$19.6B
Q3 25
$1.0B
$19.3B
Q2 25
$977.3M
$18.3B
Q1 25
$913.2M
$17.6B
Q4 24
$18.2B
Q3 24
$18.0B
Q2 24
$17.7B
Q1 24
$16.1B
Debt / Equity
BKE
BKE
RPRX
RPRX
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BKE
BKE
RPRX
RPRX
Operating Cash FlowLast quarter
$49.4M
$827.1M
Free Cash FlowOCF − Capex
$38.4M
FCF MarginFCF / Revenue
12.0%
Capex IntensityCapex / Revenue
3.4%
Cash ConversionOCF / Net Profit
1.02×
3.86×
TTM Free Cash FlowTrailing 4 quarters
$215.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BKE
BKE
RPRX
RPRX
Q4 25
$49.4M
$827.1M
Q3 25
$58.4M
$702.6M
Q2 25
$31.0M
$364.0M
Q1 25
$120.8M
$596.1M
Q4 24
$742.5M
Q3 24
$703.6M
Q2 24
$658.2M
Q1 24
$664.6M
Free Cash Flow
BKE
BKE
RPRX
RPRX
Q4 25
$38.4M
Q3 25
$46.4M
Q2 25
$19.6M
Q1 25
$111.0M
Q4 24
Q3 24
Q2 24
Q1 24
FCF Margin
BKE
BKE
RPRX
RPRX
Q4 25
12.0%
Q3 25
15.2%
Q2 25
7.2%
Q1 25
29.3%
Q4 24
Q3 24
Q2 24
Q1 24
Capex Intensity
BKE
BKE
RPRX
RPRX
Q4 25
3.4%
Q3 25
3.9%
Q2 25
4.2%
Q1 25
2.6%
Q4 24
Q3 24
Q2 24
Q1 24
Cash Conversion
BKE
BKE
RPRX
RPRX
Q4 25
1.02×
3.86×
Q3 25
1.30×
2.44×
Q2 25
0.88×
12.06×
Q1 25
1.56×
2.50×
Q4 24
3.57×
Q3 24
1.29×
Q2 24
6.45×
Q1 24
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BKE
BKE

Segment breakdown not available.

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons